arrow_back Back to App

Increased Transparency of Drug Research and Development Costs

This new law aims to increase transparency regarding the costs of drug clinical trials and research and development expenditures by drug manufacturers. This will give citizens access to information on how much it costs to develop drugs, potentially influencing discussions about drug prices and healthcare accessibility.
Key points
A public database of drug clinical trial costs will be created, accessible to everyone.
Drug manufacturers will be required to disclose detailed research and development expenditures, broken down by stages.
This information will help understand how drug prices are determined and structured.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_3160
Sponsor: Rep. Raskin, Jamie [D-MD-8]
Process start date: 2023-05-09
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pharmaceutical Research Transparency Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_3160.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-05-09.

What are the main provisions?

Key points include:

  • A public database of drug clinical trial costs will be created, accessible to everyone.
  • Drug manufacturers will be required to disclose detailed research and development expenditures, broken down by stages.
  • This information will help understand how drug prices are determined and structured.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Raskin, Jamie [D-MD-8].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Economy